142 related articles for article (PubMed ID: 11255077)
1. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.
Kashmiri SV; Iwahashi M; Tamura M; Padlan EA; Milenic DE; Schlom J
Crit Rev Oncol Hematol; 2001 Apr; 38(1):3-16. PubMed ID: 11255077
[TBL] [Abstract][Full Text] [Related]
2. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
3. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.
Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
Mol Immunol; 2003 Oct; 40(6):337-49. PubMed ID: 14522015
[TBL] [Abstract][Full Text] [Related]
4. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants.
De Pascalis R; Gonzales NR; Padlan EA; Schuck P; Batra SK; Schlom J; Kashmiri SV
Clin Cancer Res; 2003 Nov; 9(15):5521-31. PubMed ID: 14654532
[TBL] [Abstract][Full Text] [Related]
5. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
Kashmiri SV; Shu L; Padlan EA; Milenic DE; Schlom J; Hand PH
Hybridoma; 1995 Oct; 14(5):461-73. PubMed ID: 8575795
[TBL] [Abstract][Full Text] [Related]
6. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
De Pascalis R; Iwahashi M; Tamura M; Padlan EA; Gonzales NR; Santos AD; Giuliano M; Schuck P; Schlom J; Kashmiri SV
J Immunol; 2002 Sep; 169(6):3076-84. PubMed ID: 12218124
[TBL] [Abstract][Full Text] [Related]
7. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.
Iwahashi M; Milenic DE; Padlan EA; Bei R; Schlom J; Kashmiri SV
Mol Immunol; 1999; 36(15-16):1079-91. PubMed ID: 10698310
[TBL] [Abstract][Full Text] [Related]
8. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
Mol Immunol; 2004 Jul; 41(9):863-72. PubMed ID: 15261458
[TBL] [Abstract][Full Text] [Related]
9. SDR grafting--a new approach to antibody humanization.
Kashmiri SV; De Pascalis R; Gonzales NR; Schlom J
Methods; 2005 May; 36(1):25-34. PubMed ID: 15848072
[TBL] [Abstract][Full Text] [Related]
10. Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs.
Pavlinkova G; Colcher D; Booth BJ; Goel A; Wittel UA; Batra SK
Int J Cancer; 2001 Dec; 94(5):717-26. PubMed ID: 11745468
[TBL] [Abstract][Full Text] [Related]
11. Minimizing the immunogenicity of antibodies for clinical application.
Gonzales NR; De Pascalis R; Schlom J; Kashmiri SV
Tumour Biol; 2005; 26(1):31-43. PubMed ID: 15741769
[TBL] [Abstract][Full Text] [Related]
12. A CDR-grafted (humanized) domain-deleted antitumor antibody.
Slavin-Chiorini DC; Kashmiri SV; Lee HS; Milenic DE; Poole DJ; Bernon E; Schlom J; Hand PH
Cancer Biother Radiopharm; 1997 Oct; 12(5):305-16. PubMed ID: 10851481
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody.
Santos AD; Kashmiri SV; Hand PH; Schlom J; Padlan EA
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3118s-3123s. PubMed ID: 10541352
[TBL] [Abstract][Full Text] [Related]
14. Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody.
Yoon SO; Lee TS; Kim SJ; Jang MH; Kang YJ; Park JH; Kim KS; Lee HS; Ryu CJ; Gonzales NR; Kashmiri SV; Lim SM; Choi CW; Hong HJ
J Biol Chem; 2006 Mar; 281(11):6985-92. PubMed ID: 16407221
[TBL] [Abstract][Full Text] [Related]
15. Humanization by CDR grafting and specificity-determining residue grafting.
Kim JH; Hong HJ
Methods Mol Biol; 2012; 907():237-45. PubMed ID: 22907355
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct.
Pavlinkova G; Colcher D; Booth BJ; Goel A; Batra SK
Cancer Immunol Immunother; 2000 Jul; 49(4-5):267-75. PubMed ID: 10941910
[TBL] [Abstract][Full Text] [Related]
17. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
Mateo C; Moreno E; Amour K; Lombardero J; Harris W; Pérez R
Immunotechnology; 1997 Mar; 3(1):71-81. PubMed ID: 9154469
[TBL] [Abstract][Full Text] [Related]
18. TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines.
Nicolet CM; Siegel DH; Surfus JE; Sondel PM
Tumour Biol; 1997; 18(6):356-66. PubMed ID: 9372869
[TBL] [Abstract][Full Text] [Related]
19. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.
Kettleborough CA; Saldanha J; Heath VJ; Morrison CJ; Bendig MM
Protein Eng; 1991 Oct; 4(7):773-83. PubMed ID: 1798701
[TBL] [Abstract][Full Text] [Related]
20. Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
Hanf KJ; Arndt JW; Chen LL; Jarpe M; Boriack-Sjodin PA; Li Y; van Vlijmen HW; Pepinsky RB; Simon KJ; Lugovskoy A
Methods; 2014 Jan; 65(1):68-76. PubMed ID: 23816785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
